NCT06480591Recruiting
Evaluation of the Pathobiology of CALR-mutated MPN Cells
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 35 (estimated)
- First submitted
- 7 Jun 2024
- Start date
- 21 Jan 2025
- Primary completion date
- Jul 2027
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT06480591
What you commit to
- Study type: Observational
- Planned participants: 35
- From 21 Jan 2025 to the primary completion date, Jul 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Diagnosis of MPN with JAK2 V617F mutation
Who the study is looking for
- Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR).
- Age ≥ 18 years at the time of enrollment
- Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs
- CALR-positive genetic mutation
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Atrium Health Levine Cancer Coordinator of this site? Confirm its status | Charlotte | United States | Recruiting |
| Wake Forest Baptist Comprehensive Cancer Center Coordinator of this site? Confirm its status | Winston-Salem | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.